Is the shift in treatment patterns towards new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990-2022 [0.03%]
1990年至2022年瑞典药品支出数据的分解分析：新药和高价药对支出增长的影响几何？
Marie-Catherine Schaller,Ulf-G Gerdtham,Johan Jarl
Marie-Catherine Schaller
Background: Pharmaceutical expenditures (PE) are increasing worldwide, raising concerns about sustainability. However, the current price index provides an incomplete picture of this trend due to the rapid introduction of ...
Economic cost of hemodialysis and peritoneal dialysis under public-private partnership in a public tertiary care centre of Puducherry, India [0.03%]
印度浦那地区公立三级医疗中心合作下的血液透析和腹膜透析的成本分析研究
Vanjavakam Sahithya,Parthibane Sivanantham,Jeyanthi Anandraj et al.
Vanjavakam Sahithya et al.
Background: India faces over 220 000 lakh new kidney failure cases annually, requiring approximately 34 million dialysis sessions, creating a significant economic burden on the healthcare system. This study estimates the ...
Cost-effectiveness studies of brexu-cel for relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review [0.03%]
倍林妥莫双抗治疗复发/难治B细胞急性淋巴细胞白血病和套细胞淋巴瘤的成本效果研究系统评价
Asmita Priyadarshini Khatiwada,Ahmed Mostafa Ahmed Kamel,Nathorn Chaiyakunapruk et al.
Asmita Priyadarshini Khatiwada et al.
Introduction: This systematic review aims to explore the existing evidence on the cost-effectiveness of brexu-cel across different international jurisdictions. ...
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review [0.03%]
关于高风险医疗器械上市后证据生成方案的监管观点：系统性综述
Jesús Aranda,Agnieszka Dobrzynska,Maria Piedad Rosario-Lozano et al.
Jesús Aranda et al.
Introduction: The new European Medical Device Regulation has raised the bar for the clinical evaluation of medical devices to gain marketing authorization by Notified Bodies (NBs) regarding certificates of conformity in E...
Technologies and decision-support tools for health systems management: a scoping review of features and use cases [0.03%]
用于卫生系统管理的技术和决策支持工具：特征与应用场景的综述式回顾
Ericles Andrei Bellei,Renato Vargas Fernandes,Ana Carolina Bertoletti De Marchi
Ericles Andrei Bellei
Introduction: In the face of growing patient volumes, health requirements, and economic constraints, modern healthcare systems are in dire need of innovative management solutions. Despite a range of tools available to tac...
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020 [0.03%]
英国2016-2020年成人流感住院患者相关二级医疗资源利用及费用情况
Caroline de Courville,Hélène Bricout,Fabián P Alvarez et al.
Caroline de Courville et al.
Introduction: This study aims to investigate healthcare resource utilization and related costs for influenza virus infections in adults admitted into secondary care in England across four influenza seasons. ...
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell or solid organ transplantation - a perspective of the German healthcare system [0.03%]
德国医疗卫生体系中关于对中性粒细胞减少、造血干细胞或实体器官移植患者进行全球指南规范的黏菌病诊断费用的观点分析
Sebastian M Wingen-Heimann,Oliver A Cornely,Danila Seidel et al.
Sebastian M Wingen-Heimann et al.
Introduction: Mucormycosis is a rare invasive fungal infection (IFI) which is characterized by prolonged antifungal therapy, high morbidity and mortality rates, as well as increased treatment costs. ...
Correction [0.03%]
改正措施
Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer [0.03%]
新一代ALK抑制剂洛拉替尼与克唑替尼一线治疗阳性非小细胞肺癌的疗效及成本效益分析
YuQi Shang,Hao Guo
YuQi Shang
Objectives: To assess the economic value of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer at medical insurance negotiation prices from the viewpoin...